Cardiovascular effects of beta-adrenoreceptor blocking agents after intracerebroventricular administration in conscious normotensive cats.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000526:Alprenolol / Q000494:pharmacology; D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D002552:Cerebral Ventricles; D003864:Depression, Chemical; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D007267:Injections; D007545:Isoproterenol / Q000494:pharmacology; D008012:Lidocaine / Q000494:pharmacology; D008297:Male; D010096:Oxprenolol / Q000494:pharmacology; D010869:Pindolol / Q000494:pharmacology; D011217:Practolol / Q000494:pharmacology; D011343:Procaine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D013015:Sotalol / Q000494:pharmacology; D013268:Stimulation, Chemical; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D011343:Procaine; D001262:Atenolol; D010096:Oxprenolol; D000526:Alprenolol; D008012:Lidocaine; D011433:Propranolol; D013015:Sotalol; D010869:Pindolol; D007545:Isoproterenol; D011217:Practolol